echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > FDA awards MC-1 "orphan drug title" for treatment of phosphate sterol (amine) oxidase (PNPO) deficiency

    FDA awards MC-1 "orphan drug title" for treatment of phosphate sterol (amine) oxidase (PNPO) deficiency

    • Last Update: 2021-01-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Cardiovascular drug company Mediaure announced today that the U.S. Food and Drug Administration (FDA) has awarded MC-1 the "orphan drug" for the treatment of phosphate sterol (amine) oxidase (PNPO) deficiency.
    phosphate sterol (amine) oxidase (PNPO) deficiency is an autosomal recessive genetic disease characterized by severe epileptic encephalopathy in the neonatal period, is ineffective for various anti-epileptic drugs, sterol treatment is ineffective or only partially effective.
    can be controlled by phosphate acetaldehyde (PLP) single drug, PLP withdrawal after repeated seizures.
    most patients have mutations in their PNPO genes.
    Medicure will conduct Phase III clinical trials to assess the effectiveness and safety of MC-1 in treating PNPO deficiency.
    addition, the European Medicines Agency (EMA) has awarded MC-1 the title of rare pediatric disease for the treatment of seizures associated with PNPO deficiency.
    . Albert D. Friesen, CHIEF Executive Officer and Chairman of the Board of Directors, said, "MC-1 is expected to be the first FDA-approved treatment for patients with PNPO deficiency.
    the award of orphan medicine and the title of rare pediatric disease from the FDA is a milestone for MC-1."
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.